2[1]Branett HJ,Taylor DW, Eliasziw M et al. Benefit of carotid endarterectomy in patients with symptomatic moderateor severe stenosis. north american symptomatic carotid endarterectomy trial collaborators[J]. N Engl J Med,1998,339(20):1415-1425.
3[2]Chen WH,Ho DS,Ho SL et al. Prevalence of extracranial carotid and vertebral artery disease in Chinese patients with coronary artery disease[J].Stroke, 1998,29(12):631-634.
5[4]Aman BP, David MJ. Endovascular treatment of neurovascular disorders[J]. Mount Sinai JM,2004,71(1):29-41.
6[5]Kastrup A , Groschel K, Krapf H et al. Early outcome of carotid angioplasty and stenting with and without cerebral protection devices:a systematic review of the literature[J]. Stroke,2003,34(4):813-819.
7[6]Cremonesi A, Manetti R, Setacci F et al. Protected carotid stenting: clinical advantages and complications of embolic protection devices in 442 consecutive patients[J]. Stroke,2003,34:1936-1941.
8[7]Mike M. Stenting for stroke prevention debated[J].JAMA,2004, 291(13):1551-1552.
9[9]Zhang Ruiyan, Shen weifen,David HO.Percutaneous transluminalstenting in patients with catotid artery stenosis[J].China Med J,2001, 114(11):1136-1139.
3Gabriekl H M, Oli*Nra E I. Role of abciximab in the treatment of coronary artery disease. Expert Opin Biol Thex, 2006, 6(9) :935.
4Bolognese L, Faisini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or ab- ciximab on tissue - level perfasian and troponin release in high - risk acute coronary syndromes treated with percutaneous coronary interven- tions: the EVEREST trial. J Am Coll Cardiol, 2006. 47(3) :522.
5Valgimili M, Pereoco G, Bargiefi D, et al. the additive value of tirofiban administered with bhe high - dose boblus in the prevention of ischemie complication during highrisk coronary angioplasty. J Am Colt Cardiol, 2004, 4:14.
